Show Summary Details
Page of

Principles of chemotherapy 

Principles of chemotherapy
Chapter:
Principles of chemotherapy
Author(s):

David Kerr

, Daniel Haller

, and Jaap Verweij

DOI:
10.1093/med/9780199656103.003.0021

March 29, 2019: This chapter has been re-evaluated and remains up-to-date. No changes have been necessary.

Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 26 August 2019

This chapter discusses the principles of chemotherapy, and includes information on the mechanism of action of commonly available drugs (anthracyclines, Vinca alkaloids, taxenes, alkylating agents, bleomycin, platinum–based agents, antimetabolites, topoisomerase inhibitors, hormonal agents, antiandrogens, cell signalling inhibitors, and growth factor receptor inhibitors), cellular principles of chemotherapy, pharmacological principles of chemotherapy (effects of hepatic and renal impairment, pharmacogenetics, dose intensity, locoregional drug administration, increase of the dose per administration, and treatment intervals), principles of combination chemotherapy (activity as a single agent, different mechanisms of action and resistance, dose-limiting toxicities, and cell-cycle-related and biochemical interactions), and adjuvant and neoadjuvant systemic therapy.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.